Economy and macroUpdated November 5

Wyden vows scrutiny of insurers and drugmakers.

As Democrats prepare to take control of Congress in January, Oregon Sen. Ron Wyden is poised to lead the Senate Finance Committee. He says he will seek answers from insurers over delays and denials of care, and from pharmaceutical CEOs over prices; he has also criticized Trump administration drug-pricing deals as too secretive. For now, hearings and subpoenas are the immediate oversight tools. Wyden’s team has circulated plans to expand Medicare drug-price negotiations and target insurers’ business practices, but the legislative path is steep: overriding a Trump veto would require two-thirds support in both chambers.

3 publishers3 reports

Coverage started November 4